Skip to main content
PLOS One logoLink to PLOS One
. 2025 Apr 9;20(4):e0318814. doi: 10.1371/journal.pone.0318814

Insomnia and risk of all-cause dementia: A systematic review and meta-analysis

Mingxian Meng 1,2, Xiaoming Shen 1,*, Yanming Xie 3, Rui Lan 1, Shirui Zhu 1
Editor: Frances Chung4
PMCID: PMC11981150  PMID: 40202981

Abstract

Background

The evidence on the relationship between insomnia and risk of dementia, Alzheimer’s disease (AD), and Vascular dementia (VD) is not consistent. We conducted this meta-analysis to examine the evidence for the risk of developing dementia, AD, or VD in patients with all subtypes of insomnia.

Methods

A comprehensive search of PubMed, Embase, and the Cochrane Library was conducted using the following search strings: ‘Insomnia OR Sleep initiation and Maintenance disorders OR Early morning awakening’ AND ‘Dementia OR Alzheimer’s Disease OR Vascular Dementia’ AND ‘Risk’. Data extraction was done independently by two researchers. Pooled odds ratio (OR) accompanied by 95% confidence interval (CI) were calculated using either a random-effects model or a fixed-effects model. Sensitivity analyses were performed to assess the robustness of the findings. The potential for publication bias was evaluated through Egger’s test and Begg’s test.

Results

This meta-analysis included 16 studies with a combined sample size of over 9 million individuals. Pooled analyses revealed a significant association between insomnia and dementia risk (OR = 1.36; 95% CI: 1.01-1.84), with increased risks for AD (OR = 1.52; 95% CI: 1.19-1.93) and VD (OR = 2.10; 95% CI = 2.06-2.14). Subgroup analyses showed no evidence of associations between initial insomnia (OR = 1.01; 95% CI = 0.71-1.31), sleep-maintenance insomnia (OR = 0.88; 95% CI = 0.66-1.17), and early morning awakening (OR = 0.94; 95% CI = 0.83-1.07) with dementia risk. Insomnia patients from Europe (OR = 1.24; 95% CI = 1.14-1.35), Asia (OR = 2.19; 95% CI = 2.06-2.32), and the Americas (OR = 1.05; 95% CI =  1.04-1.07) had varying risks of dementia. Subgroups with less than five years of follow-up (OR = 2.16; 95% CI = 1.81-2.60) exhibited higher dementia risks in insomnia patients, while those with more than five years of follow-up (OR = 1.17; 95% CI = 1.03-1.33) showed a lower risk.

Conclusion

Our meta-analysis reveals that insomnia is linked to the risk of dementia, AD, and VD. These findings suggest that insomnia may significantly contribute to the risk of all-cause dementia, highlighting the importance of early intervention and management of insomnia. Despite our efforts to minimize and explore the sources of heterogeneity, it still remained, and therefore our results should be interpreted with caution.

Introduction

Dementia is a progressive neurodegenerative disease, with Alzheimer’s disease (AD) and vascular dementia (VD) being the two most common types [1]. Every 3 seconds, the global population of individuals with dementia increases by one, doubling every 20 years [2]. Projections indicate that by 2050, the worldwide prevalence of dementia will reach 152 million [3]. The burden imposed by dementia on families, societies, and economies is substantial, with global expenditures reaching up to one trillion dollars annually [4]. Currently, many interventions are attempted for treatment, but the effects are still unsatisfactory [5]. Given these challenges, identifying and addressing modifiable risk factors such as insomnia could be crucial in mitigating the growing public health burden of dementia [6]. According to the Lancet Commission’s 2020 report, approximately 40% of dementia cases are attributable to 12 modifiable health-related risk factors [4].

Sleep disorder is arguably a potential risk factor for dementia, albeit not encompassed within the 12 modifiable risk factors mentioned above [4]. Nearly half, or 47%, of individuals aged 65 and older are affected by sleep disorders [7]. Insomnia is the most common sleep disorder [8], with one-third of the world’s population affected by insomnia [9]. According to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), insomnia is defined by difficulty falling asleep, difficulty staying asleep, and early morning awakenings with difficulty returning to sleep [10]. Concurrently, insomnia may manifest with daytime symptoms such as fatigue, diminished energy, and difficulties with cognitive functions, which are frequently the most distressing manifestations experienced by individuals with insomnia [11].

Previous meta-analysis [1215] have shown the relationship between insomnia and the risk of all-cause dementia, encompassing AD and VD. However, conflicting findings have emerged from other studies [1618], rendering their conclusions inconclusive. Meanwhile, the precise mechanism by which insomnia contributes to dementia remains unclear. Current hypotheses suggest potential associations with neuronal inflammation [19], disrupted amyloid-beta (Aβ) protein metabolism [20], and cerebrospinal fluid Tau protein level [21].

Given the complex bidirectional relationship between insomnia and dementia, as well as a wealth of novel evidence is continually emerging concerning the association linking insomnia to the risk of all-cause dementia [16,2228]. It is imperative to comprehensively synthesize all available evidence to quantify the association between insomnia and the risk of all-cause dementia. Therefore, we conducted this meta-analysis to explore the relationship between insomnia and the risk of all-cause dementia.

Methods

The study adhered to the guidelines outlined in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [29]. The protocol has been duly registered on the International prospective register of systematic reviews PROSPERO, with the registration number CRD42024502980.

Data sources

The databases have been searched for this study encompassed PubMed, Embase, and the Cochrane Library, with a cutoff date set at January 15, 2024. We utilized a combination of medical subject headings (MeSH) and free-text keywords to ensure comprehensive coverage of relevant studies. The search terms included combinations of (“Insomnia” OR “Sleep initiation and Maintenance disorders” OR “Early morning awakening”) and (“Dementia” OR “Alzheimer Disease” OR “Vascular Dementia”) along with (“Risk”). Additionally, Boolean operators were applied to refine the results, and truncation symbols were used where applicable to capture variant word endings. The search was not limited by language or publication year, allowing us to capture studies from diverse geographical regions and timeframes. Furthermore, to maximize the comprehensiveness of the search, we reviewed reference lists of previous meta-analyses and systematic reviews [1215], identifying any additional studies that may meet our inclusion criteria. Detailed search strategies, including the exact terms and filters used, are provided in Tables S1–S3 in S1 File.

Eligibility criteria

All included studies met the following criteria: (1) cohort studies or case-control studies based on cohort trials; (2) the correlation between insomnia and the risk of all-cause dementia, Alzheimer’s disease (AD), or Vascular dementia (VD) had to be examined; (3) the exposure variable comprises insomnia and its subtypes, encompassing challenges in sleep onset, sleep maintenance, early awakening, and related factors; (4) the outcome is defined as all-cause dementia, AD or VD; (5) the studies included must provide comprehensive risk estimates, including Hazard Ratios (HR), Relative Risks (RR), or Odds Ratios (OR), accompanied by their respective 95% confidence intervals (CIs). In instances where this data is lacking, direct correspondence will be established with the authors to ensure the acquisition of precise risk estimates.

The exclusion criteria: (1) duplicated publications; (2) letters, conference abstracts, and reviews; (3) the outcome is characterized by cognitive impairment that does not progress to dementia or a decline in cognitive abilities; (4) studies that utilized the same database or investigated different aspects of the same population were considered.

Study selection

Thorough scrutiny of the literature was systematically undertaken by two independent assessors, MMX and SXM, in strict accordance with predetermined criteria for inclusion and exclusion. Initially, duplicate literature was eliminated through a combination of automated processes and manual review by individuals. Subsequently, all literature unrelated to the topic of research was excluded by carefully reviewing titles and abstracts. Finally, the remaining literature underwent a comprehensive approach, involving the downloading of full texts and meticulous reading, with strict adherence to inclusion and exclusion criteria leading to the exclusion of literature that did not meet the specified standards. Throughout the process of study selection, should discrepancies arise between assessors(MMX and SXM), the resolution is achieved through consultation with a third reviewer, XYM.

Data extraction

The full text of the included studies underwent a comprehensive review, and pertinent data, such as authors, year of publication, study design, and sample characteristics, were initially extracted. A data extraction form was then developed to outline the specific information to be collected, ensuring both consistency and completeness. Two independent reviewers performed the data extraction to guarantee the accuracy of the collected information through mutual validation [30]. In instances where clarification or additional data were required, authors of relevant studies were contacted to provide necessary details.

Risk of bias

To evaluate the literature quality, we utilized the Newcastle-Ottawa Quality Rating Scale (NOS) [31]. Independently, MMX and SXM applied the NOS to assess each included study, emphasizing three critical quality dimensions related to selection bias, Comparability Bias, and Outcome Assessment Bias. Studies scoring 7-9 points on the Newcastle-Ottawa Scale were considered high quality a with low risk of bias, 4-6 points indicated medium quality with a moderate risk of bias, and 0-3 points represented lower quality with a high risk of bias. S4 Table exhibited the specific items of the NOS quality assessment form for non-randomized controlled trials. To ensure consistency and reliability in our evaluation, any disagreements between assessors (MMX and SXM) were resolved through discussion or by seeking input from third-party reviewer (XYM).

Statistical analysis

Adjusted odds ratios (ORs) accompanied by their corresponding 95% confidence intervals (CIs) will be utilized to assess the relationship between insomnia and the risk of all-cause dementia. Heterogeneity was assessed using the χ2 test and I2 values [32]. A random-effects model was applied where I2 > 50%[33], and sources of heterogeneity were explored through subgroup analyses and meta-regression. Sensitivity analyses, crucial for ensuring the robustness of findings, will involve systematic exclusion of individual studies followed by rerunning the analysis to validate the overall effect, thereby ensuring that the correlation results are not unduly influenced by any single study [34]. To evaluate potential publication bias, visual inspection of funnel plots and statistical assessment using Egger’s test and Begg’s test will be conducted [35,36]. This step aims to identify and address potential publication bias, thereby bolstering confidence in the study outcomes. Given the complex nature of insomnia and all-cause dementia, subgroup analyses based on continent, follow-up duration, gender, number of participants, study type, and insomnia diagnostic criteria and dementia diagnostic criteria will be performed. This approach seeks to offer a nuanced and comprehensive exploration of potential variations in associations across distinct subgroups. Random-effects multivariable meta-regression analyses were performed to investigate potential sources of heterogeneity and to assess the impact of moderators, including Continent, follow-up duration, number of participants, study type, insomnia diagnostic criteria, and dementia diagnostic criteria. We also used R to visualize the scores of each part and total score of the NOS scale of the included studies. All statistical analyses were conducted by Stata statistical software (version 14.0) and R4.2.1.

Ethics statement

All analyses were based on public database; no ethical approval or patient consent was required.

Results

Study selection

A total of 1,984 studies were retrieved from the database and 398 duplicates were removed. A further 1,537 studies were excluded by reading the title and abstract. The full texts of the remaining 53 articles and the additional 5 articles from previous meta-analyses were downloaded and thoroughly examined. Ultimately, 16 studies [16,18,2228,3742] that met the inclusion and exclusion criteria were included in this meta-analysis. Specific details of each study that was read in full text and the reasons for exclusion are provided in S5 Table. The flow chart for literature screening is shown in Fig 1.

Fig 1. PRISMA flow diagram illustrating the study selection process for the meta-analysis on the association between insomnia and the risk of All-Cause dementia.

Fig 1

The flow diagram outlines the number of records identified through database searches (PubMed, Embase, Cochrane Library), the number of records screened after removing duplicates, and the number of full-text articles assessed for eligibility. It also shows the number of studies excluded at each stage, with reasons for exclusion provided during full-text assessment. Finally, the diagram highlights the total number of studies included in the qualitative synthesis and those included in the quantitative synthesis (meta-analysis).

Characteristics of included studies

A total of 16 studies were included in this meta-analysis, 11 of which were cohort studies [16,18,22,23,2527,3942] and 5 studies [17,24,28,37,38] were case-control studies; with the publication ranging from 1994 to 2023. A cumulative total of 9,016,761 individuals were enrolled in the studies, with 7 studies [1618,22,25,28,39] encompassing participants from Europe, 4 from Asia [24,37,38,40], and 5 from the Americas [23,26,27,41,42]. Among the studies incorporated in the analysis, 11 were retrospective [16,18,24,27,28,3742] in nature, while 5 were prospective [17,22,23,25,26]. The follow-up periods spanned from a minimum of 3 years to a maximum of 21 years. Self-reported questionnaires emerged as the predominant method for diagnosing insomnia, with a total of 9 studies [17,18,22,23,2527,39,41] employing this approach. Additionally, 6 studies [24,28,37,38,40,42] utilized the International Classification of Diseases (ICD) diagnostic codes, while 1 study [16] adopted the Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria. The diagnosis of dementia is primarily conducted using ICD coding. All studies, which adjusted for various confounding factors with slight variations across different investigations, presented adjusted risk estimates denoted by HR, OR, or RR, with consistent adjustments for gender and age across all research. The basic characteristics of the included studies are shown in Table 1.

Table 1. Basic characteristics of the included studies.

Author Year country Study type Sample size Follow-up
years
Age
(years)
Diagnosis of Insomnia/All-cause dementia Insomnia type Endpoint Confounders adjusted NOS scores
Selbæk-Tungevåg, S et al. 2023 Norway Retrospective
cohort study
Total:
7,492
11
averages
PID
(66.7 ± 6.5)
nPID
(67.3 ± 6.2)
DIS
(67.2 ± 6.4)
nDIS
(67.2 ± 6.2)
DMS
(67.0 ± 6.3)
nDMS
(67.3 ± 6.2)
EMA
(67.7 ± 6.7)
nEMA
(67.2 ± 6.1)
Insomnia
DSM-5
Dementia DSM-5\MoCA\WLMT
PID,
probable insomnia disorder
DIS, difficulties initiating sleep
DMS, difficulties maintaining sleep
EMA,
early morning awakenings
All-cause dementia
AD
Age, sex, marital
status, education, BMI, hypertension, stroke, diabetes, myocardial infarction, heart failure, COPD, sleep apnea, physical activity, smoking, alcohol
consumption, sub-scores for depression and anxiety on the HADS, and apolipoprotein E genotype.
8
Tan, X et al. 2023 Swedish Prospective
cohort study
Total:
22,078
19
averages
Insomnia
(60.6 ± 8.7)
nInsomnia
(59.8 ± 8.8)
Insomnia
(Karolinska Sleep Questionnaire)
dementia (ICD-9/ICD-10)
Insomnia All-cause dementia Age, sex, level, depression, social isolation,
body mass index, level of physical activity, smoking status, alcohol consumption, hypertension and diabetes.
8
Lin, W et al. 2023 TaiWan,China Retrospective case control study Total:
8,052
15
averages
Insomnia
(69.01 ± 16.88)
nInsomnia
(68.95 ± 16.59)
Insomnia (ICD-9-CM)
dementia (ICD-9-CM)
Insomnia AD sleep
disorders, gender, age groups, insured premium, catastrophic illness, diabetic mellitu, hypertension, depression, stroke, dementia, chronic kidney disease, season, location, urbanization level, level of care.
8
Wong,R et al. 2023 United States prospective
cohort study
Total:
6,284
10
averages
Insomnia
(78.28 ± 8.0)
nInsomnia
(73.65 ± 6.3)
Insomnia
(questionnaire)
Dementia
(National Health and Aging
Trends Study, NHATS algorithm)
Sleep-initiation
Insomnia
Sleep-maintenance insomnia
All-cause dementia Sociodemographics and health 8
Cavaillès, C et al. 2022 French Prospective cohort study Total:
6,851
12
averages
≥65 Insomnia
(questionnaire)
Dementia
(DSM-IV)
Difficulty with initiating sleep
Difficulty in maintaining sleep
Early morning awakening
All-cause dementia adjusted for study center, sex, mobility, and presence of the APOE-ε4 allele, stratified for the level of education, diabetes mellitus, body-mass index, and cardiovascular disease, depressive status. 8
Baek, M.S
et al.
2021 Korea Retrospective
case control study
Total:
8,390,613
7
averages
Insomnia
(59.48 ± 11.82)
nInsomnia
(59.48 ± 11.82)
Insomnia
(ICD-10)
Alzheimer’s disease
(ICD-10)
vascular dementia
(ICD-10)
Insomnia AD
VD
Age and sex 7
Robbins, R et al. 2021 United States Prospective
cohort study
Total:
6,736
8
averages
≥65 Insomnia
(questionnaire)
Dementia
(Test, Questionnaire)
Difficulty initiating sleep
Difficulty falling back asleep
Concurrent sleep difficulties (difficulty falling asleep and difficulty
falling back asleep)
All-cause dementia Age, sex, marital status, education and
chronic conditions.
7
Resciniti, N.V et al. 2021 United States Retrospective
cohort study
Total:
13,833
14
averages
66.41 ± 9.52 Insomnia
(Questionnaire)
Dementia
(HRS cognitive score)
Insomnia All-cause dementia Age, gender, race, education, body mass index, drinking, smoking status, and chronic disease index 7
Hoile, R et al. 2019 British Retrospective case-control study Total:
25,758
5
averages
≥65 Insomnia
(ICD code)
Dementia
(ICD code)
Insomnia All-cause dementia Age, gender, stroke, heart failure, mental illness, sleep apneoa, chronic pulmonry disease, hypnotics sleep apnoea 8
Hung, C.M et al. 2018 Taiwan,
China
Retrospective case-control study Total:
310,458
3
averages
Insomnia
(47.39 ± 15.69)
nInsomnia
(47.39 ± 15.69)
Insomnia
ICD-9-CM
Dementia
ICD-9-CM
Primary insomnia All-cause dementia Sex, age group, and year of index
healthcare use, diabetes, hyperlipidemia,
hypertension, coronary heart disease, chronic liver disease, and chronic kidney disease
8
Sindi, S et al. 2018 Sweden
(H70 study)
Retrospective
cohort study
Total:
437
5–9
averages
70 Insomnia
(Questionnaire)
Dementia
(DSM criteria)
Initial insomnia in late life
Short sleep duration (2-6 hours/night)
Long sleep duration (9-11 hours/night)
All-cause dementia age, sex, education, follow-up time, and study, alcohol consumption, smoking, physical activity, and cohabitant status, cardio/cerebrovascular conditions and hypnotics, hopelessness, APOEε4. 7
Sindi, S et al. 2018 Finland
(CAIDE study)
Retrospective
cohort study
Total:
703
21 averages 70.2 ± 3.5 Insomnia
(Questionnaire)
Dementia
(DSM criteria)
Midlife insomnia All-cause dementia age, sex, education, follow-up time, and study, alcohol consumption, smoking, physical activity, and cohabitant status, cardio/cerebrovascular conditions and hypnotics, hopelessness, APOEε4. 7
Yaffe, K et al. 2015 United States Retrospective cohort
study
Total:
179,738
8
averages
66.9 Insomnia
(ICD-9)
Dementia
(ICD-9)
Insomnia AD
VD
Lewy body dementia
Other dementia
Age, diabetes, hypertension,
myocardial infarction, cerebrovascular disease,
obesity, depression, income tertile, and education.
9
Chen, P.L et al. 2012 Taiwan,
China
Retrospective Cohort Study Total:
33,487
3
averages
65 Insomnia
(ICD-9-CM)
Dementia
(ICD-9-CM)
Insomnia All-cause dementia Age, sex, hypertension, diabetes, hyperlipidemia, and stroke. 7
Elwood, P.C et al. 2010 British Retrospective Cohort Study Total:
1,985
10
averages
Insomnia
(61.3)
Non-Insomnia
(61.9)
Insomnia
(Questionnaire)
Dementia
(AH4, NART, CRT, CAMCOG)
Insomnia VD Age, social class, smoking, alcohol intake, BMI, angina, ECG ischaemia and chest pain and National Adult Reading Test 7
Foley, D et al. 2001 United States Retrospective
Cohort Study
Total:
2,166
(male)
3
averages
Insomnia
(76.5 ± 3.7)
Non-Insomnia
(76.6 ± 3.9)
Insomnia
(Questionnaire)
Dementia
(DSM-III-R)
Insomnia All-cause dementia Age, education, apolipoprotein E4 status, Cognitive Abilities
Screening Instrument (CASI) score, depressive symptoms, hours of sleep, daytime
napping, coronary heart disease, and history of stroke from the baseline examination.
7
Morgan, K et al. 1994 British Prospective case-control study Total:
84
4
averages
≥65 Insomnia
(Questionnaire)
Dementia
(DSM-III-R)
Insomnia All-cause dementia Age, sex 8

Quality assessment

The NOS score of all studies included in the Meta-analysis is greater than 7, which indicates the high quality of the included studies. The total score of each study is shown in Table 1, and the detailed scores of each part for selection, comparability, exposure, and outcome are shown in S6 Table. Fig 2 gives a heatmap that illustrates the distribution of bias across the included studies, highlighting the frequency of high, moderate, and low risk of bias in various domains assessed using the Newcastle-Ottawa Scale. Each cell represents the proportion of studies falling into each risk category for a specific domain, with color gradients used to indicate varying levels of bias.

Fig 2. Bias Domains Heatmap for Included Studies.

Fig 2

The heatmap is color-coded, with darker shades indicating higher risks of bias and lighter shades representing lower risks. The domains evaluated include selection, comparability, and outcome/exposure assessment, with high scores categorized as lower risk.

Insomnia and risk of all-cause dementia

Risk of all-cause dementia.

A total of 8 studies [16,17,22,27,28,3840] among 16 studies in this Meta-analysis investigated the relationship between insomnia and risk of all-cause dementia. The pooled analyses with a random effect model showed that insomnia with a high risk of all-cause dementia (OR = 1.36; 95%CI: 1.01-1.84; I2 = 98.7%; P = 0.001). and the sensitive analysis illustrates a robust result present in S1 Fig. Fig 3 presents the forest plot illustrating the association between insomnia and the risk of all-cause dementia, demonstrating a pooled odds ratio of 1.36 (95% CI: 1.01-1.84) with significant heterogeneity (I² = 98.7%).

Fig 3. Sensitive analysis plot of the relationship between Insomnia and risk of all-cause Dementia.

Fig 3

Sensitivity analysis plot showing the impact of each individual study on the overall pooled effect size in the meta-analysis examining the relationship between insomnia and the risk of dementia. Each point represents the recalculated pooled odds ratio (OR) after omitting one study at a time. The horizontal line represents the 95% confidence interval (CI) of the overall pooled OR. The plot demonstrates that the exclusion of any single study does not significantly alter the overall effect size, indicating the robustness of the meta-analysis results.

Risk of AD.

Three studies [16,24,37] that met inclusion and exclusion criteria examined the relationship between insomnia and the risk of developing AD. A positive outcome in pool analysis confirms that insomnia was associated with a high risk of developing AD (OR = 1.52; 95%CI: 1.19-1.93; I2 = 65.8%; P = 0.054). As a result of the sensitive analysis displayed in S2 Fig, indicates that the pool analysis of insomnia and risk of AD is robust. Fig 4 demonstrates the forest plot of insomnia and risk of AD, given a pooled odds ratio of 1.52 (95% CI: 1.19-1.93) with significant heterogeneity (I² = 65.8%).

Fig 4. Forest plot illustrating the association between insomnia and the risk of all-cause dementia.

Fig 4

The plot displays the individual effect sizes (Odds Ratios, ORs) and 95% confidence intervals (CIs) for each study included in the meta-analysis. The solid squares represent the ORs for each study, with the size of the square proportional to the weight of the study in the analysis. The horizontal lines correspond to the 95% CIs. The diamond at the bottom represents the overall pooled OR and its 95% CI, calculated using a random-effects model. An OR greater than 1 indicates an increased risk of dementia associated with insomnia.

Risk of VD.

Two studies [18,37] examined the relationship between insomnia and the risk of VD. Pooled analysis shows a significant association between insomnia and the risk of vascular dementia (OR = 2.10; 95%CI = 2.06-2.14; I2 = 0; P = 0.446). Sensitive analysis reveals robust Meta-analysis results, exhibited in S3 Fig. The forest plot results are depicted in S4 Fig, illustrated the pooled odds ratio of 1.52 (95% CI: 1.19-1.93) with significant heterogeneity (I² = 65.8%).

Subtypes of insomnia and risk of all-cause dementia.

Underlying insomnia subtypes, five studies [16,23,25,26,39] examined the effectiveness of the link between initial insomnia and the risk of all-cause dementia. Pooled analysis findings point to no statistically significant association Between Initial Insomnia and risk of all-cause dementia (OR = 1.01; 95%CI = 0.77-1.31; I2 = 83.4%; P = 0.001). The results of the forest plot were shown in S5 Fig. The sensitivity analysis demonstrates the robustness of the meta-analysis results, as presented in S6 Fig.

Apart from this, four studies [16,23,25,26] research on the relationship between sleep-maintenance insomnia and risk of all-cause dementia. After pool analysis, there is no evidence to suggest that sleep-maintenance insomnia is linked to the risk of developing all-cause dementia (OR = 0.88; 95%CI = 0.66-1.17; I2 = 90.1%; P = 0.001). The forest plot results are displayed in S7 Fig. The robustness of the meta-analysis results is confirmed by the sensitivity analysis, provided in S8 Fig.

Additionally, pool analysis under two studies [16,25] also showed that early morning awakening was not associated with the risk of all-cause dementia (OR = 0.94; 95%CI = 0.83-1.07; I2 = 0; P = 0.939). The forest plot results were depicted in S9 Fig, providing an overview of the individual study estimates and pooled effect size. S10 Fig presents the sensitivity analysis, which verified the stability and reliability of the meta-analysis findings.

Meta regression

A Multivariate meta-regression analysis was performed to explore the potential sources of heterogeneity in the relationship between insomnia and dementia risk. The model included the following covariates: continent, follow-up duration, number of participants, study type, insomnia diagnosis criteria, and dementia diagnosis criteria. The results showed that no covariates were significantly associated with the effect size, including continent (p = 0.924), follow-up years (p = 0.524), number of participants (p = 0.984), study type (p = 0.527), and insomnia diagnosis criteria(p = 0.621), and dementia diagnosis criteria (p = 0.623), did not reach statistical significance. The details of meta-regression results with the risk of All-cause dementia are depicted in Table 2.

Table 2. Multivariate meta-regression analysis of factors affecting heterogeneity.

Variables Regression Coefficient (95% confidence interval) Stand Error p value
Continent -0.07 (-7.72, 7.58) 0.60 0.924
Follow-up years 0.56 (-7.12, 8.24) 0.60 0.524
Number of participants -0.06 (-31.36, 31.24) 2.46 0.984
Study type -0.50 (-7.46, 6.46) 0.55 0.527
Insomnia diagnostic criteria -0.38 (-7.43, 6.68) 0.56 0.621
Dementia diagnostic criteria 0.48 (-8.50, 9.45) 0.71 0.623

Subgroup analysis

Subgroup analysis was based on the continent of the studies, follow-up years, gender, study type, number of participants, insomnia diagnostic criteria, and dementia diagnostic criteria. The pooled results of five studies [16,17,22,28,39] from Europe showed that insomnia increased the risk of all-cause dementia (OR = 1.24), as did the pooled results of two studies [38,40] from Asia (OR = 2.19). In addition, a study [27] from the Americas also confirmed that insomnia is associated with an increased risk of all-cause dementia (OR = 1.05). Under the follow-up time subgroup, the results of the pooled analyses illustrate that follow-up time ≥  5 years [16,22,27,28] (OR = 1.17), and the follow-up time <  5 years [17,3840] (OR = 2.16). Subgroups according to gender showed that men with insomnia [40] (OR = 2.39) were more likely to develop all-cause dementia than women with insomnia [40,41] (OR = 1.72). Subgroup analysis based on study type indicated that retrospective studies[16,27,28,3840] (OR = 1.45) and prospective studies[17,22] (OR = 1.17). According to the number of participants, the subgroup analysis was performed, with the number of participants greater than or equal to 10,000[22,27,28,38,40] (OR = 1.53) and the number of participants less than 10,000[16,17,39] (OR = 1.17). For the subgroup analysis based on insomnia diagnostic criteria, patients were classified into three subgroups: DSM criteria [16], self-report [17,22,27,39], and ICD codes [28,38,40]. The results for the DSM criteria subgroup did not show a significant association with all-cause dementia. ICD codes diagnoses showed a stronger association between insomnia and the risk of All-Cause dementia (OR = 1.89) than self-report (OR = 1.11). Furthermore, subgroup analysis of dementia diagnosis indicated DSM criteria subgroup[16,17,39] had no significant association with all-cause dementia. ICD code diagnoses [22,28,38,40] showed a stronger association between insomnia and the risk of All-Cause dementia (OR = 1.68) than self-report [27] (OR = 1.05). The results of the subgroup analysis for the risk of all-cause dementia in patients with insomnia are summarized in Table 3.

Table 3. Subgroup analysis for the risk of All-Cause Dementia in patients with Insomnia.

Subgroups Included studies HR
(95%CI)
Heterogeneity
I2(%) P-value
Continent
 Europe 5 1.24(1.14, 1.35) 9.5 0.352
 American 1 1.05(1.04, 1.07)
 Asia 2 2.19(2.06, 2.32) 0 0.477
Follow-up Years
  ≥ 5 5 1.17(1.03, 1.33) 82.9 0.001
  < 5 3 2.16(1.81, 2.60) 54.9 0.109
Sex
 Male 1 2.39(1.85, 3.09)
 Female 2 1.72(1.02, 1.34) 0 0.941
Number of participants
  ≥ 10000 5 1.53(1.05, 2.23) 99.3 <0.001
 10000 <  3 1.17(0.99, 1.38) 0 0.448
Study type
 Retrospective
study
6 1.45(1.02, 2.08) 99.1 <0.001
 Prospective study 2 1.17(1.02, 1.34) 0 0.404
Insomnia diagnostic criteria
DSM code 1 1.03(0.74, 1.43)
Self report 4 1.11(1.01, 1.23) 50.2 0.111
ICD code 3 1.89(1.33, 2.68) 96.5 <0.001
Dementia diagnostic criteria
DSM code 3 1.17(0.99, 1.38) 0 0.448
Self report 1 1.11(1.01, 1.23)
ICD code 4 1.89(1.33, 2.68) 97.1 <0.001

Publication bias

A visual inspection of the funnel plots revealed no significant publication bias on the studies included in this meta-analysis. Furthermore, validation through Egger’s test (P = 0.204, P > 0.05) and Begg’s tests (P = 0.536, P > 0.05) further confirmed the absence of publication bias. The funnel diagram was presented in Fig 5.

Fig 5. Funnel plot assessing potential publication bias in studies examining the association between insomnia and the risk of all-cause dementia.

Fig 5

Each point represents an individual study included in the meta-analysis. The x-axis shows the effect size (Odds Ratios, ORs), and the y-axis represents the standard error of the log OR, a measure of study precision. Studies with larger sample sizes and greater precision appear toward the top of the plot, while smaller, less precise studies are near the bottom. Symmetry of the plot indicates the absence of publication bias, whereas asymmetry suggests potential bias or heterogeneity. The vertical dashed line represents the pooled effect size from the meta-analysis.

Discussion

Main findings

Our comprehensive analysis revealed that insomnia is significantly associated with an elevated risk of all-cause dementia, as well as AD and VD. Specifically, the risk of dementia increased by 1.36-fold, the risk of AD by 1.52-fold, and the risk of VD by 2.10-fold. However, the subtypes of insomnia, sleep initiation difficulties, sleep maintenance disorders, and early morning awakening were not associated with dementia.

Comparison with previous studies

The association between insomnia and the risk of all-cause dementia, AD, and VD has yielded conflicting findings in previous research [12,14]. A previous study [12] showed that insomnia increases the risk of all-cause dementia, which is consistent with the results of our meta-analysis. Unfortunately, their study did not analyze the relationship between insomnia and the risk of developing AD and VD. And this meta-analysis included only 5 studies, which may reduce statistical efficacy. In addition, gender confounders were not controlled for. Our study included the most recent and larger cohort studies and controlled the quality of the included studies more strictly by including only cohort studies and case-control studies. At the same time, we tightly controlled for gender factors and did not include studies with only female or male participants in the pooled analysis of insomnia and all-cause dementia risk. Our meta-analysis also found that insomnia was associated with an increased risk of AD and VD, which no meta-analysis had examined before.

While our findings align with some previous studies, the substantial heterogeneity observed underscores the complexity of the relationship between insomnia and dementia. This variability suggests that further research is needed to identify specific population subgroups or methodological factors that may influence the strength of this association.

Interpretation of findings

Drawing upon the findings of this meta-analysis and integrating them with existing evidence, we posit that insomnia is linked to a heightened risk of all-cause dementia, AD and VD. However, the precise mechanisms underlying this association remain elusive.

Amyloid-beta clearance and insomnia.

One of the key mechanisms linking insomnia to an increased risk of Alzheimer’s disease (AD) is the impaired clearance of amyloid-beta (Aβ), a hallmark of AD [43]. During sleep, the brain’s glymphatic system is more active, facilitating the removal of metabolic waste products like Aβ [20,44,45]. Studies have shown that Aβ clearance is significantly reduced during wakefulness, leading to its accumulation over time [20]. Chronic sleep deprivation, which often accompanies insomnia, may exacerbate this process, resulting in increased Aβ deposition in the brain [46]. This accumulation is believed to accelerate the onset and progression of AD, suggesting that sleep plays a critical role in neuroprotection.

Tau protein abnormalities and sleep disruption.

In addition to Aβ, abnormalities in Tau protein are another significant factor in AD pathogenesis [47]. Disrupted sleep has been shown to elevate Tau levels in both animal models and human cerebrospinal fluid (CSF), which may drive neurodegenerative changes. The study by Holth and his colleagues [21] confirmed that the sleep-wake cycle regulates the level of Tau protein in interstitial fluid, which increased by about 90% during wakefulness and by about 100% during sleep deprivation in mice, and by more than 50% during sleep deprivation in human cerebrospinal fluid (CSF), compared with the level of the protein during sleep. Given that Tau protein aggregates are a key feature of AD, chronic sleep disturbances may amplify Tau pathology, accelerating cognitive decline. The study by Rothman [48] further validated this in an Alzheimer’s disease mouse model, where sleep restriction (6 hours per day for 6 weeks) exacerbated memory deficits and increased Aβ and Tau levels in the cortex compared to controls. This provides further evidence that sleep deprivation can significantly contribute to both Aβ and Tau accumulation, highlighting the dual impact of sleep on AD pathology.

Inflammation, vascular dysfunction, and insomnia.

The association between insomnia and vascular dementia (VD) appears to be even stronger than that with AD, suggesting that vascular mechanisms may also be crucial. Chronic sleep loss is known to activate inflammatory pathways, such as nuclear factor kappa-B (NF-κB) and activator of transcription (STAT) family proteins, which can lead to vascular damage and increased risk of cerebrovascular disease [49,50]. Additionally, insomnia has been associated with white matter hyperintensities, which are markers of cerebrovascular dysfunction and are commonly observed in patients with VD [51]. This vascular pathway may explain the particularly strong link between insomnia and VD observed in our analysis, indicating that sleep disturbances could exacerbate both neurodegenerative and vascular pathways contributing to dementia.

Subgroup analyses findings.

Notably our subgroup analysis based on continent showed that Asian populations had a 2.19-fold increased risk of dementia after insomnia, followed by Europe 1.24-fold and the Americas 1.05-fold. We found that our heterogeneity decreased after subgroup analysis, so we hypothesize that this may be one of the sources of heterogeneity in this meta-analysis. We hypothesize that this phenomenon may be related to genetic predisposition, cultural differences, or variations in healthcare systems. A large case-control study [52] across multiple racial and ethnic groups confirms that the Apolipoprotein E4 (apoE4) genotype is a significant risk factor for late-onset AD, with its risk varying by race, sex, and ancestry. Specifically, the risk associated with apoE4 was higher in East Asians (OR, 4.54) than White (OR, 3.46). These findings emphasize that differently apoE4 status across populations, potentially explaining why different racial and ethnic groups show varying risks of AD. Culture and healthcare systems play a key role in cognitive ability and dementia incidence. East Asian cultures exhibit notable differences in their perceptions of sleep compared to Western cultures. For instance, a study [53] comparing Japanese and European Canadian participants found that the Japanese group perceived a weaker connection between sleep and physical health. Additionally, they reported a significantly shorter ideal sleep duration. These cultural attitudes toward sleep may influence the frequency and severity of cognitive decline associated with insomnia, as reduced sleep duration and a lack of emphasis on its health benefits could exacerbate the long-term impact of sleep disorders. Access to dementia care also differs greatly. In low-to-middle income countries of Asia, dementia is often under-recognized, and healthcare systems are not equipped to address it efficiently [54]. This contrasts with European countries that have more robust healthcare systems, where dementia is recognized earlier, and patients have better access to preventive care for conditions like insomnia [55]. This cultural and healthcare systems context may partly explain regional differences in how insomnia affects the risk of All-Cause dementia. Furthermore, we found that insomnia patients with a follow-up time greater than five years had a lower risk of dementia by subgrouping whether the follow-up time was greater than five years. However, dementia is a long-duration disease especially AD. In six cohorts comprising a total sample of 3,268 individuals, Vermunt observed that among 70-year-old patients with preclinical Alzheimer’s disease (AD), the duration of preclinical AD was 10 years, prodromal AD was 4 years, and dementia was 6 years [56]. so we are more likely to believe that the results of the subgroup analyses with more than five years of follow-up are more realistic. Subsequently, our gender subgroup analysis found that men were at greater risk of developing dementia than women. Although women report a greater incidence of insomnia [57], studies [58] have found that men tend to have more severe outcomes after the onset of insomnia. Moreover, it is reported that the combined incidence of VD and AD is greater in men than in women [59], which may contribute to the higher risk of dementia in men with insomnia. The subgroup analysis based on sample size revealed contrasting results. Studies with a sample size of Greater than or equal to 10,000 indicated a significant association between insomnia and all-cause dementia, whereas studies with fewer than 10,000 participants showed no such association, suggesting potential variability in the observed effects depending on study size. Finally, we did subgroup analyses based on insomnia diagnostic criteria demonstrated that the risk of dementia associated with insomnia was higher in studies using ICD codes for diagnosis compared to those using self-reported diagnoses. This suggests that the method of diagnosis may influence the strength of the observed association between insomnia and risk of dementia. Although most studies diagnose insomnia using questionnaires, such as the National Health and Nutrition Examination Survey (NHANES) in the United States and the UK Biobank, questionnaires may introduce bias due to participant forgetfulness or deliberate concealment. This could potentially weaken the observed association between insomnia and the risk of all-cause dementia.

Limitations and prospection

To our understanding, this systematic review represents the most extensive and thorough examination of dementia incidence among individuals with insomnia to date. We used a random-effects model to combine all effect sizes. Sensitivity analyses were performed to verify the robustness of the findings. We also used subgroup analyses and meta-regression to explore the sources of heterogeneity. Moreover, the generally high quality of the studies included in our review provides a level of confidence in the results. Nonetheless, our study does have limitations. Clinical heterogeneity and methodological heterogeneity due to differences in demographics and experimental designs are the main sources of statistical heterogeneity in this meta-analysis and cannot be completely avoided. Although we did not identify possible sources of heterogeneity, we speculate that a key limitation is the reliance on self-reported insomnia, which could lead to recall bias or misclassification. Additionally, the considerable heterogeneity observed suggests that other unmeasured factors could influence the outcomes. Therefore, the results of our meta-analysis should be interpreted with caution. Future research should prioritize the use of standardized diagnostic criteria for insomnia and incorporate objective sleep measures to reduce heterogeneity. Long-term follow-up studies, particularly those exceeding five years, are necessary to fully capture the chronic impact of insomnia on dementia risk. Additionally, large-scale, multi-center studies adjusting for key confounders will help identify at-risk populations and clarify the role of insomnia as a modifiable risk factor for dementia.

Conclusion

This meta-analysis found that insomnia is associated with increased risk of all-cause dementia, as well as AD and VD. Our findings indicate that addressing insomnia through early intervention may be a critical component in reducing the risk of dementia, including AD and VD. This highlights the importance of incorporating sleep assessments into routine clinical practice for at-risk populations.

Supporting information

S1 Fig. Sensitive analysis plot of the relationship between Insomnia and risk of all-cause dementia.

(TIF)

pone.0318814.s001.tif (421.3KB, tif)
S2 Fig. Sensitive analysis plot of the relationship between insomnia and risk of AD.

(TIF)

pone.0318814.s002.tif (99.2KB, tif)
S3 Fig. Sensitive analysis plot of the relationship between insomnia and risk of VD.

(TIF)

pone.0318814.s003.tif (48.8KB, tif)
S4 Fig. Forest plot of the relationship between insomnia and risk of VD.

(TIF)

pone.0318814.s004.tif (207.8KB, tif)
S5 Fig. Forest plot of the relationship between initial insomnia and risk of all-cause dementia.

(TIF)

pone.0318814.s005.tif (62.9KB, tif)
S6 Fig. Sensitive analysis plot of the relationship between initial insomnia and risk of all-cause dementia.

(TIF)

pone.0318814.s006.tif (31.9KB, tif)
S7 Fig. Forest plot of the relationship between sleep-maintenance insomnia and risk of all-cause dementia.

(TIF)

pone.0318814.s007.tif (407.7KB, tif)
S8 Fig. Sensitive analysis plot of the relationship between sleep-maintenance insomnia and risk of all-cause dementia.

(TIF)

pone.0318814.s008.tif (313.5KB, tif)
S9 Fig. Forest plot of the relationship between early morning awakening and risk of all-cause dementia.

(TIF)

pone.0318814.s009.tif (229.1KB, tif)
S10 Fig. Sensitive analysis plot of the relationship between early morning awakening and risk of all-cause dementia.

(TIF)

pone.0318814.s010.tif (281KB, tif)
S1 File

Supplementary Table S1-S3 Detailed search strategies. Table S1: PubMed. Table S2: Embase. Table S3: Cochran Library.

(DOC)

pone.0318814.s011.doc (39.5KB, doc)
S4 Table. NOS quality assessment form for non-randomized controlled trials.

(DOC)

pone.0318814.s012.doc (28.8KB, doc)
S5 Table. Reasons for excluded studies.

(DOC)

pone.0318814.s013.doc (141KB, doc)
S6 Table. The quality assessment of cohort and case-control studies.

(DOC)

pone.0318814.s014.doc (38KB, doc)

Data Availability

All relevant data are within the paper and its Supporting information files.

Funding Statement

The research was financially supported by the China University Industry-Academia-Research Innovation Fund--Huatong Guokang Medical Research Project under grant number 2023HT033 award to Shen Xiaoming, 2024 Henan Provincial Science and Technology Project Award Shen Xiaoming, Fund No. 242102311250 and Construction of the Double First-Class Traditional Chinese Medicine Discipline Project in Henan Province--Cultivating the Innovation Ability of Graduate Students award to Meng Mingxian (HSEP-DFCTCM-2023-8-44, HSEP-DFCTCM-2023-8-27).

References

  • 1.Oh ES, Rabins PV. Dementia. Ann Intern Med. 2019;171(5):ITC33–48. doi: 10.7326/AITC201909030 [DOI] [PubMed] [Google Scholar]
  • 2.Prince M, Wimo A, Guerchet M, Ali G-C, Wu Y-T, Prina M. World Alzheimer report 2015. The global impact of dementia: an analysis of prevalence, incidence, cost and trends: Alzheimer’s disease international. 2015.
  • 3.Gauthier S, Rosa-Neto P, Morais JA, Webster C. World Alzheimer Report 2021: Journey through the diagnosis of dementia. Alzheimer’s Disease International. 2021;2022:30. [Google Scholar]
  • 4.Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. The Lancet. 2020;396(10248):413–46. doi: 10.1016/S0140-6736(20)30367-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Lam A, Kong S, Naismith SL. Recent advances in understanding of sleep disorders and disturbances for dementia risk and prevention. Current Opinion in Psychiatry. 2023:10.1097. [DOI] [PubMed] [Google Scholar]
  • 6.Dominguez LJ, Veronese N, Vernuccio L, Catanese G, Inzerillo F, Salemi G, et al. Nutrition, Physical Activity, and Other Lifestyle Factors in the Prevention of Cognitive Decline and Dementia. Nutrients. 2021;13(11):4080. doi: 10.3390/nu13114080 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Ohayon MM, Reynolds CF 3rd. Epidemiological and clinical relevance of insomnia diagnosis algorithms according to the DSM-IV and the International Classification of Sleep Disorders (ICSD). Sleep Med. 2009;10(9):952–60. doi: 10.1016/j.sleep.2009.07.008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Sutton EL. Insomnia. Ann Intern Med. 2021;174(3):ITC33–48. doi: 10.7326/AITC202103160 [DOI] [PubMed] [Google Scholar]
  • 9.Perlis ML, Posner D, Riemann D, Bastien CH, Teel J, Thase M. Insomnia. Lancet. 2022;400(10357):1047–60. doi: 10.1016/S0140-6736(22)00879-0 [DOI] [PubMed] [Google Scholar]
  • 10.APA APA. Diagnostic and statistical manual of mental disorders. The American Psychiatric Association. 2013. [Google Scholar]
  • 11.Morin CM, Benca R. Chronic insomnia. Lancet. 2012;379(9821):1129–41. doi: 10.1016/S0140-6736(11)60750-2 [DOI] [PubMed] [Google Scholar]
  • 12.de Almondes KM, Costa MV, Malloy-Diniz LF, Diniz BS. Insomnia and risk of dementia in older adults: Systematic review and meta-analysis. J Psychiatr Res. 2016;77:109–15. doi: 10.1016/j.jpsychires.2016.02.021 [DOI] [PubMed] [Google Scholar]
  • 13.Bubu OM, Brannick M, Mortimer J, Umasabor-Bubu O, Sebastião YV, Wen Y, et al. Sleep, Cognitive impairment, and Alzheimer’s disease: A Systematic Review and Meta-Analysis. Sleep. 2017;40(1):10.1093/sleep/zsw032. doi: 10.1093/sleep/zsw032 [DOI] [PubMed] [Google Scholar]
  • 14.Shi L, Chen S-J, Ma M-Y, Bao Y-P, Han Y, Wang Y-M, et al. Sleep disturbances increase the risk of dementia: A systematic review and meta-analysis. Sleep Med Rev. 2018;40:4–16. doi: 10.1016/j.smrv.2017.06.010 [DOI] [PubMed] [Google Scholar]
  • 15.Xu W, Tan C-C, Zou J-J, Cao X-P, Tan L. Sleep problems and risk of all-cause cognitive decline or dementia: an updated systematic review and meta-analysis. Journal of Neurology, Neurosurgery & Psychiatry. 2019. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Selbæk‐Tungevåg S, Selbæk G, Strand BH, Myrstad C, Livingston G, Lydersen S, et al. Insomnia and risk of dementia in a large population‐based study with 11‐year follow‐up: The HUNT study. Journal of Sleep Research. 2023:e13820. [DOI] [PubMed] [Google Scholar]
  • 17.Morgan K, Lilley JM. Risk factors among incident cases of dementia in a representative british sample. Int J Geriat Psychiatry. 1994;9(1):11–15. doi: 10.1002/gps.930090104 [DOI] [Google Scholar]
  • 18.Elwood PC, Bayer AJ, Fish M, Pickering J, Mitchell C, Gallacher JE. Sleep disturbance and daytime sleepiness predict vascular dementia. Journal of Epidemiology & Community Health. 2010;35(5):123–30. doi: 10.1136/jech.2009.102123 [DOI] [PubMed] [Google Scholar]
  • 19.Irwin MR, Vitiello MV. Implications of sleep disturbance and inflammation for Alzheimer’s disease dementia. Lancet Neurol. 2019;18(3):296–306. doi: 10.1016/S1474-4422(18)30450-2 [DOI] [PubMed] [Google Scholar]
  • 20.Xie L, Kang H, Xu Q, Chen MJ, Liao Y, Thiyagarajan M, et al. Sleep drives metabolite clearance from the adult brain. Science. 2013;342(6156):373–7. doi: 10.1126/science.1241224 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Holth JK, Fritschi SK, Wang C, Pedersen NP, Cirrito JR, Mahan TE, et al. The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans. Science. 2019;363(6429):880–4. doi: 10.1126/science.aav2546 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Tan X, Åkerstedt T, Lagerros YT, Åkerstedt AM, Bellocco R, Adami H-O, et al. Interactive association between insomnia symptoms and sleep duration for the risk of dementia-a prospective study in the Swedish National March Cohort. Age Ageing. 2023;52(9):afad163. doi: 10.1093/ageing/afad163 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Wong R, Lovier MA. Sleep Disturbances and Dementia Risk in Older Adults: Findings From 10 Years of National U.S. Prospective Data. Am J Prev Med. 2023;64(6):781–7. doi: 10.1016/j.amepre.2023.01.008 [DOI] [PubMed] [Google Scholar]
  • 24.Lin W, Lin Y-K, Yang F-C, Chung C-H, Hu J-M, Tsao C-H, et al. Risk of neurodegenerative diseases in patients with sleep disorders: A nationwide population-based case-control study. Sleep Med. 2023;107:289–99. doi: 10.1016/j.sleep.2023.05.014 [DOI] [PubMed] [Google Scholar]
  • 25.Cavaillès C, Berr C, Helmer C, Gabelle A, Jaussent I, Dauvilliers Y. Complaints of daytime sleepiness, insomnia, hypnotic use, and risk of dementia: a prospective cohort study in the elderly. Alzheimers Res Ther. 2022;14(1):12. doi: 10.1186/s13195-021-00952-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Robbins R, Weaver MD, Barger LK, Wang W, Quan SF, Czeisler CA. Sleep difficulties, incident dementia and all‐cause mortality among older adults across 8 years: Findings from the National Health and Aging Trends Study. Journal of sleep research. 2021;30(6):e13395. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Resciniti NV, Yelverton V, Kase BE, Zhang J, Lohman MC. Time-Varying Insomnia Symptoms and Incidence of Cognitive Impairment and Dementia among Older US Adults. Int J Environ Res Public Health. 2021;18(1):351. doi: 10.3390/ijerph18010351 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Hoile R, Tabet N, Smith H, Bremner S, Cassell J, Ford E. Are symptoms of insomnia in primary care associated with subsequent onset of dementia? A matched retrospective case-control study. Aging Ment Health. 2020;24(9):1466–71. doi: 10.1080/13607863.2019.1695737 [DOI] [PubMed] [Google Scholar]
  • 29.Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Int J Surg. 2021;88:105906. doi: 10.1016/j.ijsu.2021.105906 [DOI] [PubMed] [Google Scholar]
  • 30.Taylor K, Mahtani K, Aronson J. Summarising good practice guidelines for data extraction for systematic reviews and meta-analysis. BMJ Evidence-Based Medicine. 2021;26(1):1–10. doi: 10.1136/bmjebm-2020-111456 [DOI] [PubMed] [Google Scholar]
  • 31.Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2000.
  • 32.Huedo-Medina TB, Sánchez-Meca J, Marín-Martínez F, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods. 2006;11(2):193–206. doi: 10.1037/1082-989X.11.2.193 [DOI] [PubMed] [Google Scholar]
  • 33.Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods. 2010;1(2):97–111. doi: 10.1002/jrsm.12 [DOI] [PubMed] [Google Scholar]
  • 34.Higgins JPT, Thompson SG. Controlling the risk of spurious findings from meta-regression. Stat Med. 2004;23(11):1663–82. doi: 10.1002/sim.1752 [DOI] [PubMed] [Google Scholar]
  • 35.Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–101. [PubMed] [Google Scholar]
  • 36.Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34. doi: 10.1136/bmj.315.7109.629 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Baek MS, Han K, Kwon H-S, Lee Y-H, Cho H, Lyoo CH. Risks and Prognoses of Alzheimer’s Disease and Vascular Dementia in Patients With Insomnia: A Nationwide Population-Based Study. Front Neurol. 2021;12:611446. doi: 10.3389/fneur.2021.611446 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Hung C-M, Li Y-C, Chen H-J, Lu K, Liang C-L, Liliang P-C, et al. Risk of dementia in patients with primary insomnia: a nationwide population-based case-control study. BMC Psychiatry. 2018;18(1):38. doi: 10.1186/s12888-018-1623-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Sindi S, Kåreholt I, Johansson L, Skoog J, Sjöberg L, Wang H-X, et al. Sleep disturbances and dementia risk: A multicenter study. Alzheimers Dement. 2018;14(10):1235–42. doi: 10.1016/j.jalz.2018.05.012 [DOI] [PubMed] [Google Scholar]
  • 40.Chen P-L, Lee W-J, Sun W-Z, Oyang Y-J, Fuh J-L. Risk of dementia in patients with insomnia and long-term use of hypnotics: a population-based retrospective cohort study. PLoS One. 2012;7(11):e49113. doi: 10.1371/journal.pone.0049113 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Foley D, Monjan A, Masaki K, Ross W, Havlik R, White L, et al. Daytime sleepiness is associated with 3-year incident dementia and cognitive decline in older Japanese-American men. J Am Geriatr Soc. 2001;49(12):1628–32. doi: 10.1046/j.1532-5415.2001.t01-1-49271.x [DOI] [PubMed] [Google Scholar]
  • 42.Yaffe K, Nettiksimmons J, Yesavage J, Byers A. Sleep Quality and Risk of Dementia Among Older Male Veterans. Am J Geriatr Psychiatry. 2015;23(6):651–4. doi: 10.1016/j.jagp.2015.02.008 [DOI] [PubMed] [Google Scholar]
  • 43.Yu X, Shi R, Zhou X, Zhang M, Cai Y, Jiang J, et al. Correlations between plasma markers and brain Aβ deposition across the AD continuum: Evidence from SILCODE. Alzheimers Dement. 2024;20(9):6170–82. doi: 10.1002/alz.14084 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Nedergaard M, Goldman SA. Glymphatic failure as a final common pathway to dementia. Science. 2020;370(6512):50–56. doi: 10.1126/science.abb8739 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Komaroff AL. Does Sleep Flush Wastes From the Brain? JAMA. 2021;325(21):2153–5. doi: 10.1001/jama.2021.5631 [DOI] [PubMed] [Google Scholar]
  • 46.Chen D-W, Wang J, Zhang L-L, Wang Y-J, Gao C-Y. Cerebrospinal Fluid Amyloid-β Levels are Increased in Patients with Insomnia. J Alzheimers Dis. 2018;61(2):645–51. doi: 10.3233/JAD-170032 [DOI] [PubMed] [Google Scholar]
  • 47.Abyadeh M, Gupta V, Paulo JA, Mahmoudabad AG, Shadfar S, Mirshahvaladi S, et al. Amyloid-beta and tau protein beyond Alzheimer’s disease. Neural Regen Res. 2024;19(6):1262–76. doi: 10.4103/1673-5374.386406 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Rothman SM, Herdener N, Frankola KA, Mughal MR, Mattson MP. Chronic mild sleep restriction accentuates contextual memory impairments, and accumulations of cortical Aβ and pTau in a mouse model of Alzheimer’s disease. Brain Res. 2013;1529:200–8. doi: 10.1016/j.brainres.2013.07.010 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Irwin MR, Wang M, Ribeiro D, Cho HJ, Olmstead R, Breen EC, et al. Sleep loss activates cellular inflammatory signaling. Biol Psychiatry. 2008;64(6):538–40. doi: 10.1016/j.biopsych.2008.05.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Irwin MR, Witarama T, Caudill M, Olmstead R, Breen EC. Sleep loss activates cellular inflammation and signal transducer and activator of transcription (STAT) family proteins in humans. Brain Behav Immun. 2015;47:86–92. doi: 10.1016/j.bbi.2014.09.017 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Cheng C-Y, Tsai C-F, Wang S-J, Hsu C-Y, Fuh J-L. Sleep disturbance correlates with white matter hyperintensity in patients with subcortical ischemic vascular dementia. J Geriatr Psychiatry Neurol. 2013;26(3):158–64. doi: 10.1177/0891988713493503 [DOI] [PubMed] [Google Scholar]
  • 52.Belloy ME, Andrews SJ, Le Guen Y, Cuccaro M, Farrer LA, Napolioni V, et al. APOE Genotype and Alzheimer Disease Risk Across Age, Sex, and Population Ancestry. JAMA Neurol. 2023;80(12):1284–94. doi: 10.1001/jamaneurol.2023.3599 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Cheung BY, Takemura K, Ou C, Gale A, Heine SJ. Considering cross-cultural differences in sleep duration between Japanese and Canadian university students. PLoS One. 2021;16(4):e0250671. doi: 10.1371/journal.pone.0250671 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Ferri CP, Jacob KS. Dementia in low-income and middle-income countries: Different realities mandate tailored solutions. PLoS Med. 2017;14(3):e1002271. doi: 10.1371/journal.pmed.1002271 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Schmachtenberg T, Monsees J, Thyrian JR. Structures for the care of people with dementia: a European comparison. BMC Health Services Research. 2022;22(1):1372. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Vermunt L, Sikkes SAM, van den Hout A, Handels R, Bos I, van der Flier WM, et al. Duration of preclinical, prodromal, and dementia stages of Alzheimer’s disease in relation to age, sex, and APOE genotype. Alzheimers Dement. 2019;15(7):888–98. doi: 10.1016/j.jalz.2019.04.001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Jee HJ, Shin W, Jung HJ, Kim B, Lee BK, Jung Y-S. Impact of Sleep Disorder as a Risk Factor for Dementia in Men and Women. Biomol Ther (Seoul). 2020;28(1):58–73. doi: 10.4062/biomolther.2019.192 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Suh S, Cho N, Zhang J. Sex Differences in Insomnia: from Epidemiology and Etiology to Intervention. Curr Psychiatry Rep. 2018;20(9):1–12. doi: 10.1007/s11920-018-0940-9 [DOI] [PubMed] [Google Scholar]
  • 59.Podcasy JL, Epperson CN. Considering sex and gender in Alzheimer disease and other dementias. Dialogues Clin Neurosci. 2016;18(4):437–46. doi: 10.31887/DCNS.2016.18.4/cepperson [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Rishab Gupta

8 Sep 2024

PONE-D-24-20907Insomnia and Risk of All-Cause Dementia: A Systematic Review and Meta-AnalysisPLOS ONE

Dear Dr. shen,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Oct 23 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols .

We look forward to receiving your revised manuscript.

Kind regards,

Rishab Gupta, MD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match. 

When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section.

3. Thank you for stating the following financial disclosure: 

"The author(s) received no specific funding for this work."

At this time, please address the following queries:

a) Please clarify the sources of funding (financial or material support) for your study. List the grants or organizations that supported your study, including funding received from your institution. 

b) State what role the funders took in the study. If the funders had no role in your study, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

c) If any authors received a salary from any of your funders, please state which authors and which funders.

d) If you did not receive any funding for this study, please state: “The authors received no specific funding for this work.”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

4. In the online submission form, you indicated that [The datasets used during the study are available from the public databases and corresponding author on reasonable request.]. 

All PLOS journals now require all data underlying the findings described in their manuscript to be freely available to other researchers, either 1. In a public repository, 2. Within the manuscript itself, or 3. Uploaded as supplementary information.

This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If your data cannot be made publicly available for ethical or legal reasons (e.g., public availability would compromise patient privacy), please explain your reasons on resubmission and your exemption request will be escalated for approval. 

5. Please include your full ethics statement in the ‘Methods’ section of your manuscript file. In your statement, please include the full name of the IRB or ethics committee who approved or waived your study, as well as whether or not you obtained informed written or verbal consent. If consent was waived for your study, please include this information in your statement as well. 

6. As required by our policy on Data Availability, please ensure your manuscript or supplementary information includes the following: 

A numbered table of all studies identified in the literature search, including those that were excluded from the analyses.  

For every excluded study, the table should list the reason(s) for exclusion.  

If any of the included studies are unpublished, include a link (URL) to the primary source or detailed information about how the content can be accessed. 

A table of all data extracted from the primary research sources for the systematic review and/or meta-analysis. The table must include the following information for each study: 

Name of data extractors and date of data extraction 

Confirmation that the study was eligible to be included in the review.  

All data extracted from each study for the reported systematic review and/or meta-analysis that would be needed to replicate your analyses. 

If data or supporting information were obtained from another source (e.g. correspondence with the author of the original research article), please provide the source of data and dates on which the data/information were obtained by your research group. 

If applicable for your analysis, a table showing the completed risk of bias and quality/certainty assessments for each study or outcome.  Please ensure this is provided for each domain or parameter assessed. For example, if you used the Cochrane risk-of-bias tool for randomized trials, provide answers to each of the signalling questions for each study. If you used GRADE to assess certainty of evidence, provide judgements about each of the quality of evidence factor. This should be provided for each outcome.  

An explanation of how missing data were handled. 

This information can be included in the main text, supplementary information, or relevant data repository. Please note that providing these underlying data is a requirement for publication in this journal, and if these data are not provided your manuscript might be rejected.  

Additional Editor Comments:

Dear Authors,

I have reviewed your manuscript and also noted the reviewers' comments. I recommend that you make revisions to the manuscript before it can be published.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: I Don't Know

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The article fails on many levels to be considered for publication. For instance, the risk and domains of bias are not elaborately explained. The discussion section also appears to be compromised. The heterogeneity in the means of diagnosis of insomnia is another source of concern; was heterogeneity within limits to allow for a meta-analysis? Were all studies included for systematic review as well as for meta-analysis?

The figures are often given as a passing reference and not adequately explained.

Reviewer #2: Review Comments to the Author:

Manuscript Title: "Insomnia and Risk of All-Cause Dementia: A Systematic Review and Meta-Analysis"

1. Overview: The manuscript titled "Insomnia and Risk of All-Cause Dementia: A Systematic Review and Meta-Analysis" addresses a pertinent issue in the field of sleep disorders and neurodegenerative diseases. The study aims to elucidate the association between insomnia and the risk of developing dementia, including Alzheimer's disease (AD) and Vascular dementia (VD). The manuscript is well-structured, and the research question is clearly articulated. The authors have conducted an extensive and systematic literature search and have utilized appropriate statistical methods to synthesize the findings from multiple studies.

2. Technical Soundness and Data Support: The manuscript is technically sound in many respects, and the data presented do support the authors' conclusions to a certain extent. The meta-analysis incorporates 16 studies, involving over 9 million individuals, which is commendable. The inclusion criteria are well-defined, and the studies included in the analysis are generally of high quality, as indicated by the Newcastle-Ottawa Quality Rating Scale (NOS) scores.

However, there are some concerns that need to be addressed:

Heterogeneity: One of the major concerns is the significant heterogeneity observed in the analysis, particularly in studies with shorter follow-up periods (less than five years). The high I² values in several analyses suggest that there is substantial variability among the studies, which may not be fully accounted for by the random-effects model used. The authors have performed sensitivity analyses to assess the robustness of their findings, but the persistence of heterogeneity indicates that the results should be interpreted with caution. It would be beneficial to explore the potential sources of this heterogeneity further, such as differences in population characteristics, study designs, or diagnostic criteria for insomnia and dementia.

Subgroup Analyses: The authors have conducted subgroup analyses based on continent, follow-up years, gender, and insomnia subtypes. While these analyses provide valuable insights, they also reveal substantial differences in the risk estimates across different subgroups. For example, the risk of dementia associated with insomnia is markedly higher in Asian populations compared to European and American populations. These differences may be due to a variety of factors, including genetic predisposition, cultural differences, or variations in healthcare systems. The manuscript would benefit from a more in-depth discussion of these potential explanations and their implications for the generalizability of the findings.

3. Statistical Analysis: The statistical analysis in the manuscript appears to be performed appropriately and rigorously. The authors have used both fixed-effects and random-effects models to account for heterogeneity, and they have conducted sensitivity analyses to validate the robustness of their findings. The use of Egger’s test and Begg’s test to evaluate publication bias is appropriate, and the results suggest that publication bias is not a major concern in this meta-analysis.

However, the significant heterogeneity identified in some analyses remains a concern. The use of random-effects models is justified given the heterogeneity, but it also means that the pooled estimates should be interpreted with caution. The authors may want to consider conducting additional analyses to explore the sources of heterogeneity, such as meta-regression or stratified analyses based on study characteristics.

4. Interpretation of Findings: The interpretation of the findings is generally sound, and the authors have provided a thorough discussion of the potential mechanisms underlying the association between insomnia and dementia. The discussion of amyloid-beta (Aβ) deposition, Tau protein abnormalities, and the role of inflammation in the pathogenesis of dementia is well-supported by the existing literature. The manuscript also highlights the complex bidirectional relationship between sleep disorders and neurodegeneration, which is an important consideration.

However, the manuscript could be strengthened by a more detailed discussion of the limitations of the study and the potential impact of confounding factors. For example, many of the included studies relied on self-reported questionnaires to diagnose insomnia, which may introduce recall bias or misclassification. Additionally, while the authors have adjusted for several confounders, there may be residual confounding that could influence the results. A more explicit acknowledgment of these limitations would add transparency to the manuscript and provide a more balanced interpretation of the findings.

5. Ethical Considerations: The manuscript includes an ethics statement indicating that the data were analyzed anonymously and that the datasets used during the study are available from public databases. This is consistent with ethical guidelines for meta-analyses, and no major ethical concerns are noted.

6. Additional Comments:

The manuscript could benefit from a more detailed explanation of the search strategy, including the specific keywords and search terms used, as well as any limitations in the search process. This would allow readers to better assess the comprehensiveness of the literature search.

The authors have provided a clear and concise abstract, but it would be helpful to include a brief mention of the limitations of the study in the abstract as well, to provide a more balanced summary of the findings.

The manuscript is generally well-written, but there are a few minor grammatical errors and typos that should be corrected in the final version.

7. Conclusion: In conclusion, the manuscript presents a valuable contribution to the literature on the relationship between insomnia and dementia risk. The findings are supported by a rigorous and systematic approach to data synthesis, although the significant heterogeneity observed in some analyses warrants caution in the interpretation of the results. With some revisions, the manuscript has the potential to make a meaningful impact on the understanding of sleep disorders and neurodegenerative diseases.

I recommend that the authors address the concerns regarding heterogeneity and provide a more detailed discussion of the study's limitations. With these revisions, the manuscript would be suitable for publication.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy .

Reviewer #1: No

Reviewer #2: Yes:  Ankit Chalia

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org . Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: PLOS ONE Review Ankit Chalia.docx

pone.0318814.s015.docx (35.8KB, docx)
PLoS One. 2025 Apr 9;20(4):e0318814. doi: 10.1371/journal.pone.0318814.r003

Author response to Decision Letter 1


19 Sep 2024

Dear reviewer, we have responded point by point to your questions in the file “response to reviewers”, and all the changes have been marked in red in the file “revised manuscript with track changes”.

Attachment

Submitted filename: Response to Reviewers.doc

pone.0318814.s017.doc (216KB, doc)

Decision Letter 1

Frances Chung

22 Jan 2025

Insomnia and Risk of All-Cause Dementia: A Systematic Review and Meta-Analysis

PONE-D-24-20907R1

Dear Dr.  Xiaoming

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager®  and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Frances Chung, M.B.B.S, F.R.C.P.C

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

Reviewer #2: I would like to commend the authors on their thorough and thoughtful revisions to the manuscript titled "Insomnia and Risk of All-Cause Dementia: A Systematic Review and Meta-Analysis." The improvements made have significantly enhanced the clarity, rigor, and overall quality of the manuscript. Below are some specific areas where the changes have been particularly effective:

Abstract: The abstract is now much more concise, and the emphasis on the practical implications of the findings related to early intervention for insomnia is a strong addition. This enhances the impact and relevance of the research, making it more accessible to a broad audience.

Introduction: The introduction has been refocused to highlight the importance of modifiable risk factors such as insomnia. The revised language is clearer and flows better, making the rationale for the study more compelling and easy to follow.

Methods: The detailed inclusion of the search strategy and explicit description of the keywords used significantly improve transparency. The additional clarification on how conflicts in study selection were resolved adds rigor to the methodological approach.

Results: The results section is now much clearer, particularly the subgroup analyses. The presentation of the data is more concise, and the additional context provided for the figures enhances the reader’s understanding of the key findings.

Discussion: The expanded discussion on heterogeneity provides important context for the study's findings and demonstrates a nuanced understanding of the variability in the included studies. The additional acknowledgment of study limitations, such as the use of self-reported data, further strengthens the discussion.

Conclusion: The revised conclusion does an excellent job of emphasizing the practical applications of the findings, particularly the potential for insomnia interventions to reduce dementia risk. This is a strong and clinically relevant takeaway.

Overall, the revisions have greatly improved the manuscript, and I appreciate the authors' dedication to addressing the feedback provided. The manuscript is now clearer, more concise, and better positioned to make a meaningful contribution to the field. Excellent work!

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy .

Reviewer #1: No

Reviewer #2: No

**********

Acceptance letter

Frances Chung

PONE-D-24-20907R1

PLOS ONE

Dear Dr. shen,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Frances Chung

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. Sensitive analysis plot of the relationship between Insomnia and risk of all-cause dementia.

    (TIF)

    pone.0318814.s001.tif (421.3KB, tif)
    S2 Fig. Sensitive analysis plot of the relationship between insomnia and risk of AD.

    (TIF)

    pone.0318814.s002.tif (99.2KB, tif)
    S3 Fig. Sensitive analysis plot of the relationship between insomnia and risk of VD.

    (TIF)

    pone.0318814.s003.tif (48.8KB, tif)
    S4 Fig. Forest plot of the relationship between insomnia and risk of VD.

    (TIF)

    pone.0318814.s004.tif (207.8KB, tif)
    S5 Fig. Forest plot of the relationship between initial insomnia and risk of all-cause dementia.

    (TIF)

    pone.0318814.s005.tif (62.9KB, tif)
    S6 Fig. Sensitive analysis plot of the relationship between initial insomnia and risk of all-cause dementia.

    (TIF)

    pone.0318814.s006.tif (31.9KB, tif)
    S7 Fig. Forest plot of the relationship between sleep-maintenance insomnia and risk of all-cause dementia.

    (TIF)

    pone.0318814.s007.tif (407.7KB, tif)
    S8 Fig. Sensitive analysis plot of the relationship between sleep-maintenance insomnia and risk of all-cause dementia.

    (TIF)

    pone.0318814.s008.tif (313.5KB, tif)
    S9 Fig. Forest plot of the relationship between early morning awakening and risk of all-cause dementia.

    (TIF)

    pone.0318814.s009.tif (229.1KB, tif)
    S10 Fig. Sensitive analysis plot of the relationship between early morning awakening and risk of all-cause dementia.

    (TIF)

    pone.0318814.s010.tif (281KB, tif)
    S1 File

    Supplementary Table S1-S3 Detailed search strategies. Table S1: PubMed. Table S2: Embase. Table S3: Cochran Library.

    (DOC)

    pone.0318814.s011.doc (39.5KB, doc)
    S4 Table. NOS quality assessment form for non-randomized controlled trials.

    (DOC)

    pone.0318814.s012.doc (28.8KB, doc)
    S5 Table. Reasons for excluded studies.

    (DOC)

    pone.0318814.s013.doc (141KB, doc)
    S6 Table. The quality assessment of cohort and case-control studies.

    (DOC)

    pone.0318814.s014.doc (38KB, doc)
    Attachment

    Submitted filename: PLOS ONE Review Ankit Chalia.docx

    pone.0318814.s015.docx (35.8KB, docx)
    Attachment

    Submitted filename: Response to Reviewers.doc

    pone.0318814.s017.doc (216KB, doc)

    Data Availability Statement

    All relevant data are within the paper and its Supporting information files.


    Articles from PLOS One are provided here courtesy of PLOS

    RESOURCES